Drugs / anti-MUC1 CAR-pNK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02839954 | Jul 2016 → Jul 2017 | colorectal carcinoma, gastric carcinoma, hepatocellular carcinoma, malignant glioma +2 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-MUC1 CAR-pNK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02839954 ↗ |
| Action | Deplete | “allow killing of targets underexpressing HLA-class I” PMID 28054442 ↗ Feb 2017 |
| Modality | Cell therapy | “CAR-pNK cell immunotherapy” NCT02839954 ↗ |
| Target | MUC1 | “targeting MUC1 antigen” NCT02839954 ↗ |